Recent studies have shown that neurofibrillary tangles are frequently accompanied by a-synuclein inclusions in sporadic and familial Alzheimer disease, in Down syndrome, in progressive supranuclear palsy, and Parkinsonism dementia complex of Guam. Here we report the cases of 2 brothers with familial progressive aphasia who developed features of frontotemporal dementia with predominant tau pathology but also a-synuclein pathology. The 2 patientsÕ brains revealed abundant tau pathology in the hippocampus and basal ganglia, whereas tau and a-synuclein aggregates coexisted only in the nucleus basalis of Meynert, the only region where asynuclein was present. In this brain region, abundant Lewy bodies, Lewy neurites, and tau inclusions were found; the pathology was more abundant in the older than in the younger brother. Sarkosylinsoluble tau extracted from brains of the 2 patients showed the presence of tau filaments that contained 3 major tau bands of 60, 64, and 68 kDa on Western blot analysis. These bands contained mainly tau with 3 and 4 repeats and no amino-terminal inserts and tau with 4 repeats and one amino-terminal insert. No mutations were identified in the tau, a-synuclein, b-synuclein, or parkin genes. We think that this is the first report showing a specific colocalization of neurofibrillary tangles and Lewy bodies in a family with progressive aphasia.
INTRODUCTION
Tauopathies and a-synucleinopathies define 2 distinct groups of neurodegenerative diseases: Tauopathies are disorders with characteristic filamentous inclusions made of hyperphosphorylated tau, such as Alzheimer disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration, and some forms of frontotemporal dementia (FTD) (1, 2) , whereas a-synucleinopathies are disorders characterized by eosinophilic inclusions composed of a-synuclein, such as Lewy bodies in Parkinson disease (PD) and dementia with Lewy bodies, and glial cytoplasmic inclusions in multiple system atrophy (3) (4) (5) .
Recent studies, however, have revealed the coexistence of tau and a-synuclein pathologies in some cases of neurodegenerative diseases. For example, a-synuclein in the form of Lewy bodies and Lewy neurites has recently been identified in disorders with prominent tau pathology such as familial and sporadic AD, Down syndrome, PSP, neurodegeneration with brain iron accumulation, Parkinsonism dementia complex of Guam and a case with FTD-MND (6) (7) (8) (9) (10) (11) (12) (13) . In these disorders, neurofibrillary tangles coexist with a-synuclein-positive inclusions, and the two pathologies often colocalize in certain brain regions. In AD, for example, they colocalize primarily in the amygdala. Furthermore, tau inclusions and widespread asynuclein aggregates have also been found in some of the brains of patients from the Contursi kindred with familial PD (14) , and tau pathology has been reported in a subset of Lewy bodies in the brains of patients with PD (15) . Here we report a study of 2 brothers diagnosed with progressive aphasia who developed behavioral features typical of frontotemporal dementia.
The progressive aphasias are included within the broad range of frontotemporal dementia, although some authorities prefer the general label frontotemporal lobar degeneration to describe these non-Alzheimer dementias (16, 17) . Two major forms of progressive aphasia are recognized depending on speech fluency and the nature of the comprehension disorder. Sporadic cases can typically be classified as fluent (also known as semantic dementia) or nonfluent (18) . The majority of cases of progressive aphasia are sporadic and only a few familial cases have been described to date (19) (20) (21) (22) .
The 2 patients described here presented with very similar profiles of language impairment classified as progressive nonfluent aphasia (23) . MRI scans (23) and macroscopic and microscopic examination revealed severe lefthemisphere atrophy and neuronal loss in cortical regions of the brain in both patients. Tau pathology was the main neuropathologic feature but a-synuclein pathology was also present, in the absence of b-amyloid plaques. The a-synuclein pathology was specifically localized in the nucleus basalis of Meynert where tau pathology was also present but usually in distinct neurons.
Western blot analysis and electron microscopy of sarkosyl-insoluble tau extracted from brains of the 2 patients confirmed the presence of tau filaments, which consisted mainly of 4-repeat tau isoforms and had the appearance of straight and paired helical structures. No mutations were identified in the tau, a-and b-synuclein, or the parkin coding regions or exon-intron junctions. We think that this is the first study showing the coexistence of tau and a-synuclein aggregates in a family presenting with progressive aphasia.
MATERIALS AND METHODS

Patients
Patient 1, a right-handed security gate importer, presented in April 1995 at the age of 50, complaining of progressive language impairment over 18 months. His speech was nonfluent and hesitant, with frequent word-finding pauses, phonetic paraphasias, and short phrases. He made occasional syntactic errors in speech and had difficulty understanding syntactically complex language. Formal testing showed a pattern of surface dyslexia, but his visuospatial functions, as well as memory and problem solving in nonverbal domains, were unimpaired. There were no physical signs, and his medical history of partially resolved depression was not thought to be contributory. An MRI scan was performed soon after presentation, which showed left-sided atrophy, particularly marked in polar and inferior temporal areas but also involving the frontal lobe. His deficits worsened rapidly, and by 1997 he had no useful language. He also developed more generalized cognitive deficits, obsessive and aggressive behaviors, and eventually Parkinsonism. He died in February 1999.
Patient 2, a right-handed baker, was more than 5 years older than Patient 1, but presented only in January 1996 at 56 years of age, having noticed progressive language impairments for the preceding 2 years. His spontaneous speech, like his brotherÕs, was nonfluent, with word-finding difficulty, phonetic paraphasia and grammatical errors, and he also showed a surface dyslexia and dysgraphia. Syntactic comprehension was more severely impaired than single-word comprehension. He was less anomic than Patient 1, and at presentation performed much better on tests of word production to a letter or category cue, although his performance on all these tests was well below normal levels. His nonverbal skills were largely intact, and there were no physical signs. He had been diagnosed with temporal lobe epilepsy in 1991, which was controlled on carbamazepine. He was also found to be depressed at presentation. In comparison with Patient 1, the MRI scan of Patient 2 showed less marked atrophy, which was confined to the left perisylvian region, with a milder degree of left temporal lobe involvement. His progression was rapid. He developed marked behavioral symptoms and died in residential care in November 2000. The father of both patients died in his 80s and suffered from dementia in late life, but there was no other significant family history. Neither of the patientsÕ parents had any other children. Further details of the clinical, cognitive, neuropsychologic, and brain imaging studies of the two brothers are given in Croot et al (23) .
Neuropathology
Postmortem brain examination was performed in both cases. The brain was bisected through the corpus callosum in the sagittal plane. Blocks of tissue were removed from all major cortical areas of the right cerebral hemisphere before processing through paraffin. The right cerebral hemisphere, the right cerebellar hemisphere, and the left half of the brainstem were sliced and then rapidly frozen on a brass plate precooled on dry ice to 250°C. This tissue was used for DNA analysis and for biochemical studies of tau protein. The contralateral (left) cerebral hemisphere, left cerebellar hemisphere, and right hemi-brainstem were immersed in 10% formalin saline for four weeks prior to dissection. Subsequently, the fixed cerebral hemisphere was cut coronally into 0.5-cm-thick slices, the brainstem was cut into 0.5-cm-thick slices in the horizontal plane, and the cerebellar hemisphere was cut vertically through the dentate nucleus. The fixed brain slices were sampled according to the CERAD protocol (24) and tissue blocks were processed through paraffin wax. Tenmicron sections were cut from paraffin-embedded tissue and stained with hematoxylin and eosin or used for immunohistochemistry.
Immunohistochemistry
Sections from the following brain areas of Patients 1 and 2 were studied: hippocampus, occipital cortex, entorhinal cortex, cingulate cortex, cerebellum, basal ganglia, midbrain, medulla, pons, amygdala, BrodmannÕs area 21/22, and BrodmannÕs areas 40 and 46. Sections were treated with methanol (20%)/ peroxide (1.5%) for 30 minutes prior to overnight incubation with primary antibodies at 4°C. The antibody staining was visualized using the biotin/avidin Vectastain system (Vector Laboratories, Peterborough, UK), as previously described (4) .
The following primary antibodies were used: phosphorylation-dependent anti-tau monoclonal antibodies AT8, AT100 (Autogen Bioclear, Innogenetics, Calne, UK) and 12E8 (kind gift of P. Seubert, Athena Neurosciences, Worcester, MA), antisera against amyloid-b (kind gift of V. M.-Y. Lee, University of Pennsylvania, USA), anti-ubiquitin (Dakocytomation, Ely, UK) and anti-a-synuclein Per7 (kind gift of M. Goedert, Medical Research Council, Laboratory of Molecular Biology, UK ) and S129 (kind gift of T. Iwatsubo, University of Tokyo, Japan). AT8 recognizes tau phosphorylated at S202 and T205, AT100 recognizes tau phosphorylated at T212 and S214, 12E8 recognizes tau phosphorylated at S262 and/or S356 (using the numbering of the longest human brain tau isoform). Per7 recognizes the middle region of human a-synuclein. S129 recognizes a-synuclein phosphorylated at S129. All of the above primary antibodies were used at 1/1,000. Secondary antibodies (Vector Laboratories) were used at a dilution of 1/250 and staining was developed using 3,3 diaminobenzidine (Vector Laboratories).
For double-labeling experiments with tau AT8 and asynuclein Per7 antibodies, AT8 staining was visualized using diaminobenzidine and Per7 staining was visualized with the peroxidase substrate kit Vector SG (Vector Laboratories). Sections stained with the anti-Ab antiserum were pretreated with 90% formic acid for 5 minutes. Immunohistochemistry with 12E8 was carried out in parallel on AD sections, which were used as a positive control for the antibody staining.
DNA Extraction and Sequence Analysis
Genomic DNA was extracted from blood samples of Patients 1 and 2 using DNA extraction kit (Qiagen, Crawley, UK). The following DNA sequences were analyzed: Tau exons 1, 2, 3, 4, 7, 9, 10, 11, 12, and 13; parkin exons 1-13; asynuclein exons 1-4; as well as exon-intron junctions. The coding region of b-synuclein was also analyzed by PCR amplification and sequencing of cDNA from Patients 1 and 2.
The sequences were amplified using 10 ng of genomic DNA or 5 ng of cDNA in 50 mL PCR reactions. The primers for tau, parkin, and a-synuclein were designed to target the intron-exon boundaries of each exon as described previously (25) (26) (27) . For the amplification of b-synuclein cDNA, the following primers were used: forward primer, 5#-AGCCGCCGCTCCATCCCC-3#; reverse primer, 5#-ACAGGGACAGAATGTGCTGC-3#. Amplification was performed for 35 cycles under the following conditions: Denaturation 95°C for 1 minute; annealing 50°C to 65°C (depending on the primer pair used) for 0.5 minutes; extension 72°C for 1.5 minutes, with a final 10 minute extension at 72°C. Dideoxynucleotide sequencing of double-stranded DNA was performed using the Thermo Sequenase kit and 
Semiquantitative PCR
Genomic DNA from the 2 patients and from 2 unaffected controls was used for semiquantitative PCR experiments to investigate the number of tau gene copies present in the 2 patients. Forty nanograms of genomic DNA were used in 50 mL PCR reactions. Amplification was performed for 24, 27, and 30 cycles under the following conditions: denaturation 95°C for 1 minute, annealing 55°C for 0.5 minutes, extension 72°C for 1 minute, with a final 10 min extension at 72°C. Tau gene exons 7, 9, and 13 were analyzed. The actin gene was also amplified in each PCR reaction tube and was used as an internal control for equal DNA amplification and comparison between the samples. The primer sequences used for the amplification of the actin gene are: forward primer, 5#-AGCCATGTACATAGCCATCC-3#; reverse primer, 5#-TTTGATGTCACGCACGATTT-3#. a-Synuclein gene copy number was determined using Taq Man PCR Kit (Amersham Biosciences) to specifically amplify exons 2 and 4 of the asynuclein gene in the patients and 2 controls. Furthermore, as control, exons 2 and 4 of the GAPDH gene were also amplified in both patients and control genomic DNAs.
Protein Extraction and Immunoblotting
For extraction of parkin protein, 50 mg of tissue from Patients 1 and 2 was homogenized in Tris-HCl (pH 7.4) containing protease inhibitors (Protease Inhibitors Complete Kit, Roche, Welwyn Garden City, UK). The homogenate was centrifuged at 13,000 rpm for 5 minutes and the supernatant collected. Twenty micrograms of protein were run on a 12% SDS-PAGE and immunoblotted with anti-parkin antibody (Dakocytomation) at a concentration of 1/5,000. For extraction of soluble tau, 100 mg of tissue from the frontal cortex and the hippocampus of Patients 1 and 2 and from 2 controls were dounce homogenized in 0.5 mL 2.5% perchloric acid, as previously described (28) .
Sarkosyl-insoluble tau protein was extracted from the hippocampus, as previously described (29) . Insoluble tau extracted from an AD patient was used as a control. Dephosphorylation and immunoblotting were carried out as previously described (29) . The phosphorylation-independent anti-tau antiserum BR133, specific for the amino-terminus of tau and the phosphorylation-dependent monoclonal antibodies AT8 and 12E8, was used for immunoblotting. BR133 and AT8 were used at a dilution of 1/10,000 and 12E8 was diluted 1/5,000. Peroxidase-linked secondary antibodies (Dakocytomation) were used at a dilution of 1/2,500 and the immunoblots were visualized using the ECL system (Amersham Biosciences).
Electron Microscopy
Procedures for immunoelectron microscopy were as previously described (30) . The primary antibody used was monoclonal antibody AT8, at 1/100 dilution. After incubation with the gold-labeled secondary antibody, the grids were stained with 1% lithium phosphotungstate. Micrographs were recorded at a nominal magnification of 40,0003 on a Philips EM208S microscope.
RESULTS
Neuropathology
Patient 1: Macroscopic and Microscopic Findings
The brain of Patient 1 weighed 1,020 g at the time of autopsy. The cerebral gyri of the frontal lobe were severely atrophied, especially the frontal pole and the superior frontal gyrus (Fig. 1A, 1C) . The anterior part of the temporal lobe was also severely atrophied. The frontotemporal atrophy was more marked in the left cerebral hemisphere than the corresponding areas on the right side. The medial temporal and parietal lobes were also atrophied. The caudate nucleus was slightly reduced in size with loss of the medial convexity, but other subcortical nuclei were unaffected. The brainstem and cerebellum were unremarkable. Notably, the substantia nigra and the locus coeruleus were normally pigmented with moderate cell loss.
Sections from left frontal and temporal cortical areas showed severe nerve cell loss, spongiosis, and reactive gliosis, whereas in sections from equivalent areas on the right side in the subiculum and in parietal cortex (BA 7 and 40), nerve cell loss was much less severe. The hippocampus and parahippocampal gyrus were better preserved than immediately adjacent association cortex and, within these anatomic structures, the dentate fascia and entorhinal cortex were less severely affected than SommerÕs sector. The substantia nigra showed mild nerve cell loss and the rest of the brainstem and the cerebellum showed no histologic abnormality.
Patient 2: Macroscopic and Microscopic Findings
The brain of the older brother Patient 2 (whose MRI scan at presentation showed less severe atrophy compared with Patient 1) weighed only 900 g at the time of autopsy. The cerebrum was severely atrophic. The most severely atrophied regions were the superior and inferior parietal lobules, the angular gyrus, and the superior temporal gyrus (Fig. 1B, 1D) . The orbital frontal cortex and the cingulate gyrus were least affected. The left cerebral hemisphere was more severely affected than the right hemisphere. The central white matter and the lateral ventricles were respectively reduced and dilated in proportion to the degree of cortical atrophy. The basal ganglia and thalamus were also atrophied. The substantia nigra and locus coeruleus were moderately pale and the cerebellum was unremarkable.
Light microscopy showed mild to severe neuronal loss and reactive astrocytic gliosis. The most severe degree of nerve cell loss occurred in left anterior hippocampus and entorhinal cortex, which contrasted with the relative preservation of nerve cells in the contralateral medial temporal lobe. Moderate to severe nerve cell loss was evident in frontal, temporal, and parietal association cortex. The most severely affected areas were BA 39 and BA 44/45. In the brainstem, the substantia nigra and locus ceruleus showed mild and moderate nerve cell loss, respectively.
Immunohistochemistry
Immunohistochemistry experiments revealed abundant tau-positive neuronal and glial inclusions in the dentate gyrus, the CA2 and CA3 areas in the hippocampus, and in the entorhinal cortex. Some tau-positive inclusions were also seen in the basal ganglia of both patients. The tau inclusions were stained with phosphorylation-dependent antibodies AT8 and AT100. In the affected areas, neurofibrillary tangles, tau neurites, and neuropil threads were observed (Fig. 2) . Some tufted astrocytes were also present in the entorhinal cortex of Patient 2 (Fig. 2D) .
Tau pathology was present in the same regions in the brains of the 2 brothers, but it was more abundant in Patient 2, with more numerous tau inclusions and denser neuropil threads. More marked neuronal loss was also observed in Patient 2 in the tau-affected areas. Anti-tau antibody 12E8 did not stain any neurons or glial deposits, although it stained tangles in an AD control brain. a-Synuclein-positive Lewy bodies and Lewy neurites, immunoreactive with Per7 and S129 antibodies, localized specifically in the area of the nucleus basalis of Meynert in both patients (Fig. 3) . Hyperphosphorylated tau inclusions, in the form of neurofibrillary tangles and tau-positive neurites were also present in the same groups of cells in this area. Double immunostaining with AT8 and Per-7 antibodies showed that tau and asynuclein inclusions usually did not colocalize within the same cell (Fig. 3) . The distribution of tau and a-synuclein pathology in the 2 cases was similar, but it was overall less abundant in Patient 1 and was accompanied by less marked neuronal loss compared with Patient 2. In both patients, the amygdala was not greatly affected and mainly did not contain tau or asynuclein inclusions. No immunoreactivity for b-amyloid was found in the brain of either patient and immunostaining for ubiquitin was normal.
Genetic Analysis
Genomic DNA sequencing of Patients 1 and 2 showed wild-type sequence for the tau gene. Patient 1 was homozygous for the less common H2 tau haplotype and Patient 2 was heterozygous H1/H2 (31) . Furthermore, we performed semiquantitative PCR experiments to investigate the tau gene copy number in the 2 patients. Our experiments did not show any difference in the tau gene copy numbers compared with controls, therefore excluding the possibility of any abnormal tau gene amplification.
After the identification of a-synuclein-positive Lewy bodies and Lewy neurites in the brains of these patients, the a-synuclein gene was sequenced but no mutations were identified. Furthermore, Taq Man PCR analysis of the asynuclein gene showed a normal copy number.
In search of a potential genetic factor involved in the development of both tau and a-synuclein pathology in these rare cases, we screened the parkin gene sequence. Several studies have linked parkin protein dysfunction, independently, to both a-synuclein and tau in neurodegenerative disorders (26, (32) (33) (34) . In our study, we identified no mutations in the sequence of the parkin gene, and from our biochemical analysis the parkin protein in the 2 patients was similar to controls on immunoblots. The b-synuclein gene was also studied as it has been suggested that dysfunction of b-synuclein can lead to a-synuclein aggregation (35) . Sequencing of the b-synuclein cDNA showed wild-type sequence.
Tau Protein Extraction, Dephosphorylation, and Immunoblotting
Normal levels of 3-repeat and 4-repeat tau isoforms were present in soluble tau extracted from the hippocampus (Fig. 4A ) and frontal cortex (not shown) in the brains of Patients 1 and 2. Sarkosyl-insoluble tau extracted from the hippocampus of Patients 1 and 2 appeared as 3 major bands of 60, 64, and 68 kDa following immunoblotting with tau antiserum BR133 (Fig. 4B) . The same pattern was seen with antibody AT8. In contrast, the phosphorylation-dependent anti-tau antibody 12E8, which labeled the paired helical filament (PHF)-tau pathology of the AD control, failed to label the sarkosylinsoluble tau bands of Patients 1 and 2 (data not shown). Following alkaline phosphatase treatment, the sarkosylinsoluble aggregates resolved into three major bands that aligned with tau isoforms with 4R + 1N, 4R + 0N, 3R + 0N, and a very weak band that aligned with 3R + 1N, when compared with the six recombinant tau isoforms (Fig. 4C) .
Electron Microscopy of Tau Filaments
Electron microscopy of immunolabeled preparations identified tau-positive filaments in sarkosyl-insoluble material from the hippocampus of Patients 1 and 2 (Fig. 5 ). Filaments were labeled by the phosphorylation-dependent monoclonal antibody AT8, and the majority of them had PHF morphology (Fig. 5A, 5B) . A small minority of the filaments extracted from the brain of Patient 2 were straight filaments (Fig. 5C) . 
DISCUSSION
The majority of cases of progressive aphasia are sporadic, and only very few familial cases have been described to date (19) (20) (21) (22) . Furthermore, the information available on the neuropathology of familial cases is limited. Our study describes the neuropathology, genetics, and tau biochemistry of a rare case of familial FTD with progressive aphasia.
The 2 brothers presented at 50 and 56 years of age (Patients 1 and 2, respectively) with very similar clinical and neuropsychologic features. Their clinical history revealed that they had both suffered from depression in the years before presentation. At the time of presentation, both brothers had marked deficits in expressive language abilities, with a similar profile on linguistic neuropsychologic tests (23) . In both cases, more global dementia developed quite rapidly with marked behavioral changes. The disease duration from onset to death was 4 years in both.
The classification of focal dementia syndromes remains controversial. According to the Neary et al consensus criteria (16), the brothers would fulfill criteria for progressive nonfluent aphasia, which is considered a subform of frontotemporal lobar degeneration. With the McKhann classification (17), they would be considered as language presentations of FTD. It is notable that both developed behavioral changes typical of FTD justifying their inclusion within the broad range of FTD. A recent large two-center clinicopathologic study of 61 cases with FTD syndromes suggested a strong association between a presentation with progressive nonfluent aphasia and the presence of tau-positive inclusions, but unlike the present cases, those included in the joint Sydney-Cambridge series were typically older and with a more indolent course (18) . The combined pathology present in the 2 brothers appears to be a hallmark of rapidly progressive dementia.
Their father had died at the age of 80 and in his last years he was demented. They had no other siblings and no other history of neurologic disorder in the family. The majority of familial cases of FTD appear to segregate in an autosomal dominant manner, but familial cases with tau mutations of incomplete penetrance or of recessive pattern of inheritance have also been described (36) (37) (38) . Incomplete penetrance or recessive pattern of inheritance could be the case in the 2 brothers described here.
Autopsy revealed a greatly reduced brain size in both patients: 1,020 g and 900 g for Patients 1 and 2, respectively. Both showed severe brain atrophy and, despite some differences in the overall pattern of cortical involvement, they shared characteristic marked left hemisphere temporal lobe atrophy, commonly associated with language deficits.
Numerous neurofibrillary tangles were seen in the brains of the 2 patients, and they were more abundant in Patient 2 than in Patient 1. Interestingly, similarly to tau in Pick bodies (39) , these tangles were not stained with antibody 12E8, which stained tangles in AD. This observation suggests a close link between the pathology seen in the 2 brothers and that seen in FTD with Pick bodies and in some FTDP-17 cases, such as the K257T and K369I tau mutations (40, 41) . Indeed, although the majority of tau aggregates had a neurofibrillary tangle-like shape, some inclusions similar to Pick bodies could also be detected.
Biochemically, although the sarkosyl-insoluble tau aggregates resolved into three major bands, as those observed in AD and some FTDP-17 cases, the pattern observed after dephosphorylation revealed a unique tau isoform composition. Indeed, following alkaline phosphatase treatment, the sarkosyl-insoluble bands resolved into three major bands corresponding to the two short 4R (4R + 0N, 4R + 1N) and the shortest 3R (3R + 0N) tau isoforms, which aggregated to form PHF and straight filaments, as seen by electron microscopy. A barely visible band aligning with 3R + 1N tau isoform could also be observed.
The most interesting, and previously undescribed, finding was the existence of a generalized tau pathology accompanied by the presence of a-synuclein aggregates only in the nucleus basalis of Meynert. Because this unique neuropathologic feature was present in the brains of both patients, it is unlikely that the coexistence of tau and a-synuclein aggregates is coincidental or represents a chance event in a highly affected brain region. Instead, it suggests the existence of a specific common pathway involved in the development of this disorder.
In particular, it is unlikely that this is a case of frontotemporal dementia with incidental Parkinson disease or Lewy body diseases, as Lewy bodies were not present in the substantia nigra, the area characteristically affected in PD and in amygdala or entorhinal cortex, areas affected in incidental Lewy body disease. The substantia nigra showed mild to moderate nerve cell loss in both patients, but there were no tau or asynuclein inclusions.
The characteristic localization of the two pathologies present specifically in the Meynert nucleus also differentiates this case from other disorders with both a-synuclein and tau inclusions. Most of the cases reported to date show colocalization of the inclusions primarily in the amygdala (6); and in rare cases with PSP and PD, the tau and a-synuclein aggregates are colocalized in neurons of the substantia nigra (9, 10) .
As the coexistence of tau and a-synuclein inclusions has been recently described in several cases of neurodegenerative diseases, some studies have investigated the existence of a synergistic effect in the abnormal aggregation of the two proteins (42) . Although the exact mechanism leading to formation of tau and a-synuclein aggregates is not yet known, the two proteins may share interacting mechanisms of aggregate formation and a-synuclein could prompt tau aggregation.
In our study, however, tau and a-synuclein inclusions colocalize in the same brain area but usually not in the same cells. Furthermore, a-synuclein aggregates are absent in other brain regions where tau deposits are still present, questioning a straightforward synergistic effect of the two pathologies. As mentioned, it is possible that a genetic defect is the cause of both pathologies. In search for a potential genetic defect underlying the pathway that led to the development of this disorder, we screened several genes that could have been involved.
Our genetic analysis did not identify any mutations in the tau gene. Despite the similar clinical and neuropathologic pattern of disease progression, the 2 brothers showed a different age of onset and, interestingly, the younger brother with earlier age of onset was homozygous for the H2 tau (H2/H2) haplotype, whereas his older brother was heterozygous H1/H2. Although it is not yet clear how the two distinct tau gene haplotypes may influence the FTD phenotype, it is possible that the tau H2 allele leads to an earlier age of onset in FTD patients without tau gene mutations (43) . In a recent study of how the tau haplotypes may influence disease susceptibility, it has been suggested that the H1 and H2 haplotypes show different transcriptional activity in human cell lines, with H1 being more efficient at driving tau gene expression (44) . No mutations were identified in the parkin, asynuclein, or b-synuclein genes, and so the genetic factor responsible for the development of tau and a-synuclein pathology in this familial case remains unknown. Its identification will shed some light on the relationship between tau and a-synuclein pathologies.
